Multiple myeloma in elderly patients: Prognostic factors and outcome

European Journal of Haematology

Volumn 75, Issue 5, 2005, Pages 370-375

  Anagnostopoulos, Athanasios ^a   Gika, Dimitra ^a   Symeonidis, Argyris ^b   Zervas, Konstantinos ^c   Pouli, Anastasia ^d   Repoussis, Panagiostis ^e   Grigoraki, Vassiliki ^f   Anagnostopoulos, Nikolaos ^f   Economopoulos, Theophanis ^a   Maniatis, Alice ^g   Dimopoulos, Meletios Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c THEAGENIO CANCER HOSPITAL   (Greece)

^d Agios Savvas Oncological Hospital   (Greece)

^e METAXA CANCER HOSPITAL   (Greece)

^f IASO GENERAL HOSPITAL   (Greece)

^g HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Age; Elderly; International Staging System; Multiple myeloma; Prognostic factors

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE;

AGED; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PLASMACYTOSIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANEMIA; ENZYME TESTS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 26844556860     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00532.x     Document Type: Article

References (19)

1. WISLOFF F, ANDERSEN P, ANDERSSON TR, BRANDT E, EIKA C, FJAESTAD K, LY B, LOVASEN K, STROM BR, TJONNFJORD GE. Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. Eur J Haematol 1991;47:333-337.
2. BERGSAGEL D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells 1995;13(Suppl. 2):1-9.
3. CARLI PM, BAILLY F, TAVERNIER C, MILAN C, HEUDES D, LAVAULT JF. Multiple myeloma: epidemiological features in a well-defined population in Burgundy, France. Int J Epidemiol 1989;18:330-333.
4. LUDWIG H, FRITZ E, FRIEDL HP. Epidemiologic and age-dependent data on multiple myeloma in Austria. J Natl Cancer Inst 1982;68:729-733.
5. BLADE J, MUNOZ M, FONTANILLAS M, et al. Treatment of multiple myeloma in elderly people: long-term results in 178 patients. Age Ageing 1996;25:357-361.
6. RICCARDI A, MORA O, BRUGNATELLI S, et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 1998;77:485-491.
7. FROOM P, QUITT M, AGHAI E. Multiple myeloma in the geriatric patient. Cancer 1990;66:965-967.
8. RODON P, LINASSIER C, GAUVAIN JB, BENBOUBKER L, GOUPILLE P, MAIGRE M, LUTHIER F, DUGAY J, LUCAS V, COLOMBAT P. Multiple myeloma in elderly patients: presenting features and outcome. Eur J Haematol 2001;66:11-17.
9. PHEKOO KJ, SCHEY SA, RICHARDS MA, BEVAN DH, BELL S, GILLETT D, MOLLER H. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004;127:299-304.
10. COHEN HJ, SILBERMAN HR, FORMAN W, BARTOLUCCI A, LIU C. Effects of age on responses to treatment and survival of patients with multiple myeloma. J Am Geriatr Soc 1983;31:272-277.
11. CLAVIO M, CASCIARO S, GATTI AM, et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica 1996;81:238-244.
12. HJORTH M, HOLMBERG E, RODJER S, TURESSON I, WESTIN J, WISLOFF F. Survival in conventionally treated younger (< 60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG). Eur J Haematol 1999;62:271-277.
13. ATTAL M, HAROUSSEAU JL, STOPPA AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
14. GREIPP PR, SAN MIGUEL J, DURIE BG, LOISEAU HA, FONSECA R, JACOBSON JL, RASMUSSEN E, CROWLEY JJ. Development of an International Prognostic Index (IPI) for myeloma: report of the International Myeloma Working Group. Hematol J 2003;4(Suppl. 1):S42.
15. BLADE J, SAMSON D, REECE D, APPERLEY J, BJORKSTRAND B, GAHRTON G, GERTZ M, GIRALT S, JAGANNATH S, VESOLE D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
16. PALVA IP, AHRENBERG P, ALA-HARJA K, et al. Treatment of multiple myeloma in old patients. Finnish Leukaemia Group. Eur J Haematol 1989;43:328-331.
17. GREIPP PRSMJ, DURIE BG, LOISEAU HA, FONSECA R, JACOBSON JL, RASMUSSEN E, CROWLEY JJ. A New International Staging System (ISS) for Multiple Myeloma (MM) from the International Myeloma Working Group. Blood 2003;102:190a.
18. BARLOGIE B, SMALLWOOD L, SMITH T, ALEXANIAN R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med 1989;110:521-525.
19. ALEXANIAN R, BALCERZAK S, BONNET JD, GEHAN EA, HAUT A, HEWLETT JS, MONTO RW. Prognostic factors in multiple myeloma. Cancer 1975;36:1192-1201.